• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed

    2/16/21 5:08:15 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APRE alert in real time by email
    SC 13D/A 1 a21-6693_6sc13da.htm SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13D

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULE 13d-l(a) AND AMENDMENTS THERETO FILED PURSUANT

    TO RULE 13d-2(a)

     

    (Amendment No. 5)*

     

    Aprea Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    03836J102

    (CUSIP Number)

     

    Rebecca Lucia

    5AM Venture Management, LLC

    501 2nd Street, Suite 350

    San Francisco, CA 94107

    (415) 993-8565

     

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    February 11, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ¨

     


    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     


     

    CUSIP No. 03836J102

    13D

    Page 2 of 13

     

    1.

    Name of Reporting Persons

     

    5AM Ventures IV, L.P.

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)

    o

     

    (b)

    x(1)

    3.

    SEC USE ONLY

     

     

    4.

    Source of Funds (see instructions)

     

    WC

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization


    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0

     

    8.

    Shared Voting Power

     

    594,392  shares of common stock (2)

     

    9.

    Sole Dispositive Power

     

    0

     

    10.

    Shared Dispositive Power

     

    594,392  shares of common stock (2)

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    594,392  shares of common stock (2)

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row 11

    2.8%  (3)

     

    14.

    Type of Reporting Person (see instructions)

     

    PN

     

     


    (1)         This Schedule 13D is filed by 5AM Partners IV, LLC (“5AM Partners IV”), 5AM Ventures IV, L.P. (“5AM IV”),  5AM Co-Investors IV, L.P. (“5AM Co-Investors IV”), 5AM Opportunities I, L.P. (“5AM Opportunities”), 5AM Opportunities I (GP), LLC (“5AM Opportunities GP”), Dr. John D. Diekman (“Diekman”), Andrew J. Schwab (“Schwab”) and Dr. Scott M. Rocklage (“Rocklage” and, with 5AM Partners IV, 5AM IV, 5AM Co-Investors IV, 5AM Opportunities, 5AM Opportunities GP, Diekman and Schwab, collectively, the “Reporting Persons”).  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)         These shares are held by 5AM IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV.

    (3)         Percentage based on 21,186,827 shares of Common Stock outstanding as of November 6, 2020 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020.

     


     

    CUSIP No. 03836J102

    13D

    Page 3 of 13

     

    1.

    Name of Reporting Persons

     

    5AM Co-Investors IV, L.P.

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)

    o

     

    (b)

    x(1)

    3.

    SEC USE ONLY

     

     

    4.

    Source of Funds (see instructions)


    WC

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0

     

    8.

    Shared Voting Power

     

    24,765  shares of common stock (2)

     

    9.

    Sole Dispositive Power

     

    0

     

    10.

    Shared Dispositive Power

     

    24,765  shares of common stock (2)

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    24,765  shares of common stock (2)

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row 11

     

    0.1%  (3)

     

    14.

    Type of Reporting Person (see instructions)

     

    PN

     

     


    (1)         This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)         These shares are held by 5AM Co-Investors IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM Co-Investors IV.

    (3)         Percentage based on 21,186,827 shares of Common Stock outstanding as of November 6, 2020 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020.

     


     

    CUSIP No. 03836J102

    13D

    Page 4 of 13

     

    1.

    Name of Reporting Persons

     

    5AM Partners IV, LLC

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)

    o

     

    (b)

    x(1)

    3.

    SEC USE ONLY

     

     

    4.

    Source of Funds (see instructions)

     

    AF

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0

     

    8.

    Shared Voting Power

     

    619,157  shares of common stock (2)

     

    9.

    Sole Dispositive Power

     

    0

     

    10.

    Shared Dispositive Power

     

    619,157  shares of common stock (2)

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    619,157  shares of common stock (2)

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row 11

     

    2.9%  (3)

     

    14.

    Type of Reporting Person (see instructions)

     

    OO

     

     


    (1)         This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)         Includes (i) 594,392  shares held by 5AM IV; and (ii) 24,765  shares held by 5AM Co-Investors IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

    (3)         Percentage based on 21,186,827 shares of Common Stock outstanding as of November 6, 2020 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020.

     


     

    CUSIP No. 03836J102

    13D

    Page 5 of 13

     

    1.

    Name of Reporting Persons

     

    5AM Opportunities I, L.P.

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)

    o

     

    (b)

    x(1)

    3.

    SEC USE ONLY

     

     

    4.

    Source of Funds (see instructions)


    WC

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0

     

    8.

    Shared Voting Power

     

    0

     

    9.

    Sole Dispositive Power

     

    0

     

    10.

    Shared Dispositive Power

     

    0

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row 11

     

    0

     

    14.

    Type of Reporting Person (see instructions)

     

    PN

     

     


    (1)         This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     


     

    CUSIP No. 03836J102

    13D

    Page 6 of 13

     

    1.

    Name of Reporting Persons

     

    5AM Opportunities I (GP), LLC

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)

    o

     

    (b)

    x(1)

    3.

    SEC USE ONLY

     

     

    4.

    Source of Funds (see instructions)

     

    AF

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0

     

    8.

    Shared Voting Power

     

    0

     

    9.

    Sole Dispositive Power

     

    0

     

    10.

    Shared Dispositive Power

     

    0

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    0

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row 11

     

    0

     

    14.

    Type of Reporting Person (see instructions)

     

    OO

     

     


    (1)         This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

     


     

    CUSIP No. 03836J102

    13D

    Page 7 of 13

     

    1.

    Name of Reporting Persons

     

    Dr. John D. Diekman

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)

    o

     

    (b)

    x(1)

    3.

    SEC USE ONLY

     

     

    4.

    Source of Funds (see instructions)

     

    AF

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    United States

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0

     

    8.

    Shared Voting Power

     

    619,157  shares of common stock (2)

     

    9.

    Sole Dispositive Power

     

    0

     

    10.

    Shared Dispositive Power

     

    619,157  shares of common stock (2)

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    619,157  shares of common stock (2)

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row 11

     

    2.9%  (3)

     

    14.

    Type of Reporting Person (see instructions)

     

    IN

     

     


    (1)         This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)         Includes (i) 594,392  shares held by 5AM IV; and (ii) 24,765  shares held by 5AM Co-Investors IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

    (3)         Percentage based on 21,186,827 shares of Common Stock outstanding as of November 6, 2020 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020.

     


     

    CUSIP No. 03836J102

    13D

    Page 8 of 13

     

    1.

    Name of Reporting Persons

     

    Andrew J. Schwab

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)

    o

     

    (b)

    x(1)

    3.

    SEC USE ONLY

     

     

    4.

    Source of Funds (see instructions)

     

    AF

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    United States

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0

     

    8.

    Shared Voting Power

     

    619,157  shares of common stock (2)

     

    9.

    Sole Dispositive Power

     

    0

     

    10.

    Shared Dispositive Power

     

    619,157  shares of common stock (2)

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    619,157  shares of common stock (2)

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row 11

     

    2.9%  (3)

     

    14.

    Type of Reporting Person (see instructions)

     

    IN

     

     


    (1)         This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)         Includes (i) 594,392  shares held by 5AM IV; and (ii) 24,765  shares held by 5AM Co-Investors IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

    (3)         Percentage based on 21,186,827 shares of Common Stock outstanding as of November 6, 2020 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020.

     


     

    CUSIP No. 03836J102

    13D

    Page 9 of 13

     

    1.

    Name of Reporting Persons

     

    Dr. Scott M. Rocklage

     

    2.

    Check the Appropriate Box if a Member of a Group (see instructions)

     

    (a)

    o

     

    (b)

    x(1)

    3.

    SEC USE ONLY

     

     

    4.

    Source of Funds (see instructions)

     

    AF

     

    5.

    Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)

     

    ¨

    6.

    Citizenship or Place of Organization

     

    United States

     

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    7.

    Sole Voting Power

     

    0

     

    8.

    Shared Voting Power

     

    619,157  shares of common stock (2)

     

    9.

    Sole Dispositive Power

     

    0

     

    10.

    Shared Dispositive Power

     

    619,157  shares of common stock (2)

     

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    619,157  shares of common stock (2)

     

    12.

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (see instructions)

     

    ¨

    13.

    Percent of Class Represented by Amount in Row 11

     

    2.9%  (3)

     

    14.

    Type of Reporting Person (see instructions)

     

    IN

     

     


    (1)         This Schedule 13D is filed by the Reporting Persons.  The Reporting Persons expressly disclaim status as a “group” for purposes of this Schedule 13D.

    (2)         Includes (i) 594,392  shares held by 5AM IV; and (ii) 24,765  shares held by 5AM Co-Investors IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

    (3)         Percentage based on 21,186,827 shares of Common Stock outstanding as of November 6, 2020 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020.

     


     

    CUSIP No. 03836J102

    13D

    Page 10 of 13

     

    Explanatory Note:    This Amendment No. 5 (the “Amendment”), which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on October 17, 2019, as amended by Amendment No. 1 filed May 22, 2020, as amended by Amendment No. 2 filed June 11, 2020, as amended by Amendment No. 3 filed October 7, 2020 and as amended by Amendment No. 4 filed on November 18, 2020 (the “Original Schedule 13D”) is being filed on behalf of 5AM Partners IV, LLC (“5AM Partners IV”), 5AM Ventures IV, L.P. (“5AM IV”), 5AM Co-Investors IV, L.P. (“5AM Co-Investors IV”), 5AM Opportunities I, L.P. (“5AM Opportunities”), 5AM Opportunities I (GP), LLC (“5AM Opportunities GP”),  Dr. John D. Diekman (“Diekman”), Andrew J. Schwab (“Schwab”) and Dr. Scott M. Rocklage (“Rocklage” and, with 5AM Partners IV, 5AM IV, Co-Investors IV, 5AM Opportunities, 5AM Opportunities GP, Diekman and Schwab, collectively, the “Reporting Persons”) in respect of the Common Stock, $0.001 par value per share of Aprea Therapeutics, Inc., a Delaware corporation (the “Issuer”).  This Amendment is being filed by the Reporting Persons to report open market sales of Common Stock on February 11, 2021. Accordingly, the number of securities beneficially owned by the Reporting Persons has decreased as described in Items 4 and 5 below.

     

    Item 4 and 5 of the Original Schedule 13D are hereby amended and supplemented to the extent hereinafter expressly set forth and, except as amended and supplemented hereby, the Original Schedule 13D remains in full force and effect.  All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Original Schedule 13D.

     

    Item 4.   Purpose of Transaction

     

    Item 4 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraphs at the end of Item 4:

     

    On February 3, 2021, 5AM Opportunities sold an aggregate of 138,497 shares of Common Stock in an open market transaction at a price of $7.01 per share.

     

    On February 11, 2021, 5AM IV sold an aggregate of 595,200 shares of Common Stock in an open market transaction at a price of $8.00 per share and 5AM Co-Investors IV sold an aggregate of 24,800 shares of Common Stock in an open market transaction at a price of $8.00 per share.

     


     

    CUSIP No. 03836J102

    13D

    Page 11 of 13

     

    Item 5.   Interest in Securities of the Issuer

     

    Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) — (b). The following information with respect to the ownership of the Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of February 16, 2021:

     

    Reporting Persons

     

    Shares Held
    Directly

     

    Sole Voting
    Power

     

    Shared
    Voting
    Power(1)

     

    Sole
    Dispositive
    Power

     

    Shared
    Dispositive
    Power (1)

     

    Beneficial
    Ownership

     

    Percentage
    of Class (2)

     

    5AM IV

     

    594,392

     

    0

     

    594,392

     

    0

     

    594,392

     

    594,392

     

    2.8

    %

    5AM Co-Investors IV

     

    24,765

     

    0

     

    24,765

     

    0

     

    24,765

     

    24,765

     

    0.1

    %

    5AM Partners IV (1)

     

    0

     

    0

     

    619,157

     

    0

     

    619,157

     

    619,157

     

    2.9

    %

    5AM Opportunities

     

    0

     

    0

     

    0

     

    0

     

    0

     

    0

     

    0.0

    %

    5AM Opportunities GP

     

    0

     

    0

     

    0

     

    0

     

    0

     

    0

     

    0.0

    %

    Diekman (1)

     

    0

     

    0

     

    619,157

     

    0

     

    619,157

     

    619,157

     

    2.9

    %

    Schwab (1) 

     

    0

     

    0

     

    619,157

     

    0

     

    619,157

     

    619,157

     

    2.9

    %

    Rocklage (1) 

     

    0

     

    0

     

    619,157

     

    0

     

    619,157

     

    619,157

     

    2.9

    %

     


    (1)         Includes 594,392  shares of Common Stock held by 5AM IV and 24,765  shares of Common Stock held by 5AM Co-Investors IV.  Diekman, Schwab and Rocklage, as Managing Members of 5AM Partners IV, share voting and investment authority over the shares held by 5AM IV and 5AM Co-Investors IV.

     

    (2)         Percentage based on 21,186,827 shares of Common Stock outstanding as of November 6, 2020 as disclosed in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on November 6, 2020.

     

    (c)    Except as set forth herein, none of the Reporting Persons has effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

     

    (d)    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)    The Reporting Persons ceased to be the beneficial owners of more than five percent of the Common Stock on February 11, 2021.

     


     

    CUSIP No. 03836J102

    13D

    Page 12 of 13

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date:  February 16, 2021

     

     

    5AM Ventures IV, L.P.

     

     

     

     

    By:

    5AM Partners IV, LLC,

     

     

    Its General Partner

     

     

     

     

     

     

     

    By:

    /s/ Andrew J. Schwab

     

     

    Andrew J. Schwab

     

     

    Managing Member

     

     

     

     

     

     

     

    5AM Co-Investors IV, L.P.

     

     

     

     

    By:

    5AM Partners IV, LLC,

     

     

    Its General Partner

     

     

     

     

     

     

     

    By:

    /s/ Andrew J. Schwab

     

     

    Andrew J. Schwab

     

     

    Managing Member

     

     

     

     

     

     

     

    5AM Partners IV, LLC

     

     

     

     

     

     

     

    By:

    /s/ Andrew J. Schwab

     

     

    Andrew J. Schwab

     

     

    Managing Member

     

     

     

     

     

     

     

    5AM Opportunities I, L.P.

     

     

     

     

    By:

    5AM Opportunities I (GP), LLC,

     

     

    Its General Partner

     

     

     

     

     

     

     

    By:

    /s/ Andrew J. Schwab

     

     

    Andrew J. Schwab

     

     

    Managing Member

     

     

     

     

     

     

     

    5AM Opportunities I (GP), LLC

     

     

     

     

     

     

     

    By:

    /s/ Andrew J. Schwab

     

     

    Andrew J. Schwab

     

     

    Managing Member

     

     

     

     

     

     

     

    DR. JOHN D. DIEKMAN

     

     

     

     

     

     

     

    By:

    /s/ Dr. John D. Diekman

     

     

    Dr. John D. Diekman

     


     

    CUSIP No. 03836J102

    13D

    Page 13 of 13

     

     

    ANDREW J. SCHWAB

     

     

     

     

     

     

     

    By:

    /s/ Andrew J. Schwab

     

     

    Andrew J. Schwab

     

     

     

     

     

     

     

    DR. SCOTT M. ROCKLAGE

     

     

     

     

     

     

     

    By:

    /s/ Dr. Scott M. Rocklage

     

     

    Dr. Scott M. Rocklage

     


    Get the next $APRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APRE

    DatePrice TargetRatingAnalyst
    8/20/2021Neutral → Underweight
    JP Morgan
    8/16/2021Buy → Hold
    Berenberg
    8/16/2021$6.00 → $4.00Neutral
    HC Wainwright & Co.
    8/13/2021$6.00 → $5.00Sector Perform
    RBC Capital
    8/13/2021$5.00 → $3.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $APRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $5,073 worth of shares (5,700 units at $0.89), increasing direct ownership by 21% to 33,433 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:05:34 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Duey Marc bought $25,000 worth of shares (21,459 units at $1.17), increasing direct ownership by 9% to 256,155 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    12/11/25 8:31:55 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

    DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea at an important time, following the Company's recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive wit

    2/4/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

    Approximately 50% reduction in target lesion and greater than 90% decrease in CA-125 observed in endometrial cancer patientThe unconfirmed partial response (uPR) that was observed in the first scan has been achieved at the 150 mg dose, with 220 mg cohort currently enrolling in the ACESOT-1051Potential dose-response trend observed with increasing single-agent activity across the 70 mg, 100 mg, and 150 mg cohortsData provide early clinical proof-of-concept for single-agent APR-1051 in patients with advanced solid tumors DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing i

    1/29/26 8:27:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

    DOYLESTOWN, Pa., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that it has entered into a securities purchase agreement with new and existing healthcare focused institutional investors and certain insiders of the Company to sell an aggregate of 6,288,857 shares of common stock (or pre-funded warrants in-lieu thereof), together with warrants to purchase up to an aggregate 6,288,857 shares of common stock, in a private placement priced at-the-market under

    1/29/26 8:25:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    SEC Filings

    View All

    Aprea Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

    1/29/26 4:16:39 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Aprea Therapeutics Inc.

    SCHEDULE 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

    1/28/26 2:02:13 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Aprea Therapeutics, Inc. (0001781983) (Filer)

    1/23/26 4:45:38 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President/CEO Gilad Oren bought $25,009 worth of shares (28,100 units at $0.89), increasing direct ownership by 8% to 373,720 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:08:08 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SrVP/CFO/Prin Fin & Acct Ofcr Hamill John P. bought $5,073 worth of shares (5,700 units at $0.89), increasing direct ownership by 21% to 33,433 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    2/2/26 4:05:34 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Duey Marc bought $25,000 worth of shares (21,459 units at $1.17), increasing direct ownership by 9% to 256,155 units (SEC Form 4)

    4 - Aprea Therapeutics, Inc. (0001781983) (Issuer)

    12/11/25 8:31:55 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Aprea Therapeutics downgraded by JP Morgan

    JP Morgan downgraded Aprea Therapeutics from Neutral to Underweight

    8/20/21 5:10:20 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics downgraded by Berenberg

    Berenberg downgraded Aprea Therapeutics from Buy to Hold

    8/16/21 7:29:48 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Aprea Therapeutics with a new price target

    HC Wainwright & Co. reiterated coverage of Aprea Therapeutics with a rating of Neutral and set a new price target of $4.00 from $6.00 previously

    8/16/21 6:35:21 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Financials

    Live finance-specific insights

    View All

    Aprea Therapeutics Reports Second Quarter 2022 Financial Results and Provides Update on Business Operations

    BOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways today reported financial results for the three and six months ended June 30, 2022 and provided a business update. "This is an exciting time for Aprea as we advance our ATR program into clinical development this year, continue to progress our WEE1 program toward IND submission and leverage our unique discovery platform capabilities to build for future success," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. "We believe o

    8/11/22 4:15:00 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

    BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. ("Atrin") and reported financial results for the three months ended March 31, 2022. Business Operations Update:  On May 16, 2022 Aprea completed the acquisition of Atrin, a privately held biotechnology company focused on the discovery and development of novel therapeutics targeting proteins in the DNA damage response, or DDR, pathway in oncology through synthetic lethality. The Company believes its cash and cash

    5/16/22 9:21:33 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs

    BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on its clinical trials of eprenetapopt in combination with azacitidine in its myeloid malignancy programs. The partial clinical hold does not apply to the Company's ongoing clinical trials in lymphoid malignancies and solid tumors, or the APR-548 clinical trial. There are approximately 20 patients currently receiving eprenetapopt in combination with azacitidine i

    8/5/21 5:00:00 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Leadership Updates

    Live Leadership Updates

    View All

    Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

    DOYLESTOWN, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies that exploit cancer-specific vulnerabilities while minimizing damage to healthy cells, today announced the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor. Dr. Kennedy joins Aprea at an important time, following the Company's recent early clinical proof-of-concept demonstrated in its ongoing Phase 1 dose-escalation study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. He is a highly accomplished physician scientist and biopharmaceutical executive wit

    2/4/26 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Appoints Michael Grissinger to the Board of Directors

    --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

    4/17/25 7:00:00 AM ET
    $ACET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

    DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ:APRE) ("Aprea", or the "Company"), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea's potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology, including the development of a WEE1 inhibitor (azenosertib) from early to late-stage clinical development. Dr. Pultar has vast experience in clinical development within both large and early-stag

    10/9/24 8:30:00 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Aprea Therapeutics Inc.

    SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

    10/10/24 4:07:13 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Aprea Therapeutics Inc.

    SC 13G - Aprea Therapeutics, Inc. (0001781983) (Subject)

    2/14/24 8:00:11 AM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Aprea Therapeutics Inc. (Amendment)

    SC 13G/A - Aprea Therapeutics, Inc. (0001781983) (Subject)

    2/7/24 6:55:18 PM ET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care